Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH)
Background: To assess characteristics, risk group distribution, and prognosis of patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) in Finland. Methods: Clinical chart review of patients with PAH or CTEPH recorded between 2008 and 2019 and li...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | JHLT Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S295013342400140X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864281837338624 |
|---|---|
| author | Markku Pentikäinen Piia Simonen Helena Tuunanen Pauliina Leskelä Terttu Harju Pertti Jääskeläinen Christian Asseburg Minna Oksanen Erkki Soini Christina Wennerström Airi Puhakka Terttu Harju Elina Heliövaara Pertti Jääskeläinen Katriina Kahlos Pentti Korhonen Tiina Kyllönen Pauliina Leskelä Kirsi Majamaa-Voltti Piia Simonen Anu Turpeinen Helena Tuunanen Ville Vepsäläinen Tapani Vihinen |
| author_facet | Markku Pentikäinen Piia Simonen Helena Tuunanen Pauliina Leskelä Terttu Harju Pertti Jääskeläinen Christian Asseburg Minna Oksanen Erkki Soini Christina Wennerström Airi Puhakka Terttu Harju Elina Heliövaara Pertti Jääskeläinen Katriina Kahlos Pentti Korhonen Tiina Kyllönen Pauliina Leskelä Kirsi Majamaa-Voltti Piia Simonen Anu Turpeinen Helena Tuunanen Ville Vepsäläinen Tapani Vihinen |
| author_sort | Markku Pentikäinen |
| collection | DOAJ |
| description | Background: To assess characteristics, risk group distribution, and prognosis of patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) in Finland. Methods: Clinical chart review of patients with PAH or CTEPH recorded between 2008 and 2019 and linkage to official mortality data. Results: We identified 627 patients, with 502 (80%) diagnosed after 2008, yielding an incidence of PAH and CTEPH of 4.0 and 2.9/million/year, respectively. The median time from symptoms to diagnosis was 1 year. Mean age at diagnosis of PAH patients (n = 268) was 57 years, 73% were women, 40% had idiopathic PAH, 28% associated with connective tissue diseases, and 15% with congenital heart disease, 9% had ≥3 cardiovascular comorbidities. At 1 year, 34%/34%/24%/8% were at the low/intermediate-low/intermediate-high/high Compera 2.0 risk classification groups. Survival was 91.3%, 74.8%, and 62.6% at 1, 3, and 5 years, respectively, with an improving trend over calendar time. Ten PAH patients had a lung transplant. PAH subtype, cardiac output, and the presence of ischemic heart disease or type 2 diabetes predicted survival.CTEPH patients (n = 189) were 63 years (mean) at diagnosis and 49% were women. Of the CTEPH patients, 29% underwent pulmonary endarterectomy (PEA) and 22% were treated with balloon pulmonary angioplasty. Survival was 94.6%, 87.2%, and 79.4% at 1, 3, and 5 years, respectively. PEA patients were younger, had fewer comorbidities, and had longer survival than non-PEA patients. Conclusions: Incidence and survival of PAH and CTEPH patients in Finland were similar to previously presented data for other countries. |
| format | Article |
| id | doaj-art-e062c0d7f4d54128bacd9ef66fa17c24 |
| institution | Kabale University |
| issn | 2950-1334 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHLT Open |
| spelling | doaj-art-e062c0d7f4d54128bacd9ef66fa17c242025-02-09T05:01:58ZengElsevierJHLT Open2950-13342025-02-017100191Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH)Markku Pentikäinen0Piia Simonen1Helena Tuunanen2Pauliina Leskelä3Terttu Harju4Pertti Jääskeläinen5Christian Asseburg6Minna Oksanen7Erkki Soini8Christina Wennerström9Airi Puhakka10Terttu Harju11Elina Heliövaara12Pertti Jääskeläinen13Katriina Kahlos14Pentti Korhonen15Tiina Kyllönen16Pauliina Leskelä17Kirsi Majamaa-Voltti18Piia Simonen19Anu Turpeinen20Helena Tuunanen21Ville Vepsäläinen22Tapani Vihinen23Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Corresponding author: Markku Pentikäinen, Helsinki University Hospital, Haartmaninkatu 4, P.O. Box 340, 00029 HUS, Helsinki, Finland.Helsinki University Hospital and University of Helsinki, Helsinki, FinlandTurku University Hospital, Turku, FinlandTampere University Hospital, Tampere, FinlandOulu University Hospital, Oulu, FinlandKuopio University Hospital, Kuopio, FinlandESiOR Oy, Kuopio, FinlandESiOR Oy, Kuopio, FinlandESiOR Oy, Kuopio, FinlandJanssen-Cilag AB, Solna, SwedenJanssen-Cilag Oy, Espoo, FinlandOulu University Hospital, Oulu, FinlandHelsinki University Hospital and University of Helsinki, Helsinki, FinlandKuopio University Hospital, Kuopio, FinlandOulu University Hospital, Oulu, FinlandTampere University Hospital, Tampere, FinlandOulu University Hospital, Oulu, FinlandTampere University Hospital, Tampere, FinlandOulu University Hospital, Oulu, FinlandOulu University Hospital, Oulu, FinlandKuopio University Hospital, Kuopio, FinlandTurku University Hospital, Turku, FinlandKuopio University Hospital, Kuopio, FinlandSatasairaala Hospital, Pori, FinlandBackground: To assess characteristics, risk group distribution, and prognosis of patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) in Finland. Methods: Clinical chart review of patients with PAH or CTEPH recorded between 2008 and 2019 and linkage to official mortality data. Results: We identified 627 patients, with 502 (80%) diagnosed after 2008, yielding an incidence of PAH and CTEPH of 4.0 and 2.9/million/year, respectively. The median time from symptoms to diagnosis was 1 year. Mean age at diagnosis of PAH patients (n = 268) was 57 years, 73% were women, 40% had idiopathic PAH, 28% associated with connective tissue diseases, and 15% with congenital heart disease, 9% had ≥3 cardiovascular comorbidities. At 1 year, 34%/34%/24%/8% were at the low/intermediate-low/intermediate-high/high Compera 2.0 risk classification groups. Survival was 91.3%, 74.8%, and 62.6% at 1, 3, and 5 years, respectively, with an improving trend over calendar time. Ten PAH patients had a lung transplant. PAH subtype, cardiac output, and the presence of ischemic heart disease or type 2 diabetes predicted survival.CTEPH patients (n = 189) were 63 years (mean) at diagnosis and 49% were women. Of the CTEPH patients, 29% underwent pulmonary endarterectomy (PEA) and 22% were treated with balloon pulmonary angioplasty. Survival was 94.6%, 87.2%, and 79.4% at 1, 3, and 5 years, respectively. PEA patients were younger, had fewer comorbidities, and had longer survival than non-PEA patients. Conclusions: Incidence and survival of PAH and CTEPH patients in Finland were similar to previously presented data for other countries.http://www.sciencedirect.com/science/article/pii/S295013342400140Xpulmonary arterial hypertensionchronic thromboembolic pulmonary hypertensionreal-world evidenceregistry studysurvival |
| spellingShingle | Markku Pentikäinen Piia Simonen Helena Tuunanen Pauliina Leskelä Terttu Harju Pertti Jääskeläinen Christian Asseburg Minna Oksanen Erkki Soini Christina Wennerström Airi Puhakka Terttu Harju Elina Heliövaara Pertti Jääskeläinen Katriina Kahlos Pentti Korhonen Tiina Kyllönen Pauliina Leskelä Kirsi Majamaa-Voltti Piia Simonen Anu Turpeinen Helena Tuunanen Ville Vepsäläinen Tapani Vihinen Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH) JHLT Open pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension real-world evidence registry study survival |
| title | Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH) |
| title_full | Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH) |
| title_fullStr | Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH) |
| title_full_unstemmed | Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH) |
| title_short | Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH) |
| title_sort | pulmonary hypertension in finland 2008 2020 a descriptive real world cohort study finpah |
| topic | pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension real-world evidence registry study survival |
| url | http://www.sciencedirect.com/science/article/pii/S295013342400140X |
| work_keys_str_mv | AT markkupentikainen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT piiasimonen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT helenatuunanen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT pauliinaleskela pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT terttuharju pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT perttijaaskelainen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT christianasseburg pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT minnaoksanen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT erkkisoini pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT christinawennerstrom pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT airipuhakka pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT terttuharju pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT elinaheliovaara pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT perttijaaskelainen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT katriinakahlos pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT penttikorhonen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT tiinakyllonen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT pauliinaleskela pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT kirsimajamaavoltti pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT piiasimonen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT anuturpeinen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT helenatuunanen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT villevepsalainen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah AT tapanivihinen pulmonaryhypertensioninfinland20082020adescriptiverealworldcohortstudyfinpah |